Home › Funds › Synergy Asset Management, LLC › ASND
Synergy Asset Management, LLC position in ASND
ASCENDIS PHARMA A/S · Health Care
Synergy Asset Management, LLC reported holding 91,228 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$24.3M, representing 2.29% of its reported portfolio and ranking #14 among its reported holdings. Synergy Asset Management, LLC has disclosed ASND holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Synergy Asset Management, LLC's ASND position evolved
Synergy Asset Management, LLC first disclosed a stake in ASND in Q1 2026 at 70,456 shares (US$16.1M). The position peaked in Q2 2026 at 91,228 shares, worth US$24.3M. Across 2 filings, Synergy Asset Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 91,228 shares valued at US$24.3M — an increase of 20,772 shares quarter over quarter.. Notable position changes include a 29% increase in Q2 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 70.46K | $16.12M | New |
| Q2 2026 | 91.23K | $24.33M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 43 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
More on Synergy Asset Management, LLC
FAQ
How long has Synergy Asset Management, LLC held ASND?
Synergy Asset Management, LLC has disclosed ASND holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Synergy Asset Management, LLC's current position in ASND?
As of Q2 2026, Synergy Asset Management, LLC holds 91.23K shares of ASND (ASCENDIS PHARMA A/S), valued at $24.33M, representing 2.29% of its reported portfolio and ranking #14.
Has Synergy Asset Management, LLC been buying or selling ASND?
In the latest 13F filing (Q2 2026), Synergy Asset Management, LLC increased its position in ASND. The position peaked in Q2 2026 at 91.23K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.